Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-09-30 06:00 GMT | Update On 2023-09-30 10:59 GMT

As per the latest Indian position statement released in the Journal of the Association of Physicians of India, August 2023 issue, Linagliptin therapy is simplifying the management of T2DM with efficacy & applicability across a wide range of patients.

Key expert opinions from this Position paper include:

1. 94.3% of Healthcare Professionals (HCPs) opined that a single 5 mg once daily dosing of linagliptin across diverse T2DM patient profiles, irrespective of cardiac, renal, or hepatic comorbidities, eases up management of T2DM

2. Linagliptin is used in both Drug naïve and uncontrolled T2DM patients.

Linagliptin has multiple clinical and safety advantages across a wide group of T2DM patients, making it potentially an evergreen oral anti-diabetic agent and combination of Linagliptin & Dapagliflozin and Evergreen DUO.

Reference:

Mithal, A., et.al. (2023). Simplifying Type 2 DM Care with Linagliptin: A Position Paper. The Journal of the Association of Physicians of India, 71(8), 11–12. https://doi.org/10.59556/japi.71.0324

#index-1-ad-before, #index-2-ad-before, #index-3-ad-before, #index-2-ad-before{min-height: 0px !important;}#inside_post_content_ad_1{display:none !important;} #inside_post_content_ad_2{display:none!important;}

Full View

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Linagliptin applicable across wide group of T2DM patients- Latest Indian Position Paper

Similar News